U.S. Markets closed

Sarepta plans second Duchenne drug application this year

Staff
Sarepta plans second Duchenne drug application this year

With one drug already being considered by the FDA, Sarepta Therapeutics Inc. is now planning to submit another drug for Duchenne muscular dystrophy to the FDA this year.